Buy AbbVie, stock still worth owning even as Humira fades, Barron’s says

AbbVie’s blockbuster drug Humira faces patent expirations, but there’s a lot more to it than the immunosuppressive, Teresa Rivas writes in this week’s edition of Barron’s. The company has profitable products that have begun to fill the gap left by Humira’s decline. Investors who preferred to wait out the transition from Humira may have erred — AbbVie stock is up by more than 19%, to a recent $162, so far in 2022. Moreover, the stock looks cheap and has a handsome dividend yield. It’s worth owning-now, the author argues. Reference Link